Is Champions Oncology Inc (CSBR) overvalued? · P/E 16, rev $56.9M
Champions Oncology Inc (CSBR) is a biotechnology company listed on US.
This page asks whether Champions Oncology Inc (CSBR) looks expensive on cached numbers — not a short thesis.
Latest reported CSBR revenue for 2025-04-30 was $56.9M. Net income was $4.7M. CSBR currently screens at market cap $99.8M and trailing P/E 16.0.
CSBR currently screens at market cap $99.8M and trailing P/E 16.0. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next CSBR 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the CSBR stock page for the full model, not this heading.
Not investment advice.